Stockreport

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen, Inc.  (OCGN) 
PDF GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potent [Read more]